News Quantified

NAMS – newamsterdam pharma company n.v. - ordinary shares (US:NASDAQ)

NewAmsterdam Pharma to Present at the Guggenheim Emerging Outlook: Biotech Summit

1/21

07:17 am

nams

Medium

NewAmsterdam Pharma (NASDAQ:NAMS) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.

Atherosclerotic Cardiovascular Disease Market to Register Incremental Growth at a CAGR of 4.9% During the Forecast Period (2025–2034) | DelveInsight [Yahoo! Finance]

NewAmsterdam Pharma Highlights 2025 Achievements and Outlines 2026 Strategic Priorities

NewAmsterdam Pharma (NASDAQ:NAMS) had its "outperform" rating reaffirmed by analysts at Leerink Partners.

Live Event: Join our next subscriber-only event: "The Data Driven Investor"

Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}